German China

USA: Life Sciences Bruker Appoints New Member to Board of Directors

Source: Press release

Bruker Corporation announced that its Board of Directors has appointed Philip Ma, Ph.D. to serve on its board, effective as of April 1, 2022.

Related Vendor

Dr. Philip Ma is Chief Executive Officer, President, and Founder of Prognomiq.
Dr. Philip Ma is Chief Executive Officer, President, and Founder of Prognomiq.
(Source: Business Wire)

Billerica/USA — Life sciences company Bruker has extended its board of directors with the addition of Philip Ma. Dr. Ma is Chief Executive Officer, founder, and a director of Prognomiq, a privately held healthcare company that is developing next-generation, transformative multiomics products to enable early cancer detection and cancer treatment selection and monitoring assays. Before Prognomiq, Dr. Ma was Chief Business Officer, President, and co-founder of proteomics company Seer. Prior to this, he was Vice President for Digital Health Technologies and Data Sciences at Biogen. Before joining Biogen, Dr. Ma was Senior Partner at McKinsey & Company, where he served global leaders in the pharmaceutical and biotech sectors, leading the West Coast Healthcare Practice and global Personalized Medicine practice. Dr. Ma was a macromolecular crystallographer at the Massachusetts Institute of Technology, where he earned his Ph.D. in biology. Philip also has an A.B. degree in biochemistry from Harvard University, and a M.Phil in economics from Oxford University, where he was a Rhodes Scholar.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent

(ID:48112630)